TrialNature medicine2024

Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.

Martin Schuler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.